Working with NPL enabled Lightpoint Medical to perform the pre-clinical evaluation of their product more effectively. They gained confidence in the probe's performance in an experimental environment that reflected the real world, and this could not have been achieved in another way.
The probe is currently nearing the end of its product development phase, and funding has been secured from Innovate UK to initiate the first in-man study. This clinical trial will enable CE Mark and FDA approval in 2020 for sentinel lymph node biopsy; this short trial time was possible by using pre-approved drugs.
The laparoscopic device will be used for intra-operative detection of sentinel lymph nodes and lymph node metastasis during prostate cancer surgery. Currently, high-risk prostate cancer patients undergo a full removal of the pelvic lymph nodes, an invasive procedure that leaves patients with significant complications often resulting in additional treatment. A commercialised miniature probe will allow surgeons to detect cancer cells precisely during surgery and spare healthy tissue, potentially improving patient outcomes while reducing complications and healthcare costs. The device is a significant step to solving the problem of cancerous tissue detection in the surgical field, and will be the first in the world to be approved and commercialised.
Lightpoint Medical has been shortlisted for the Collaborate to Innovate awards, held by The Engineer magazine, to recognise the significance of the collaborative work conducted through this project.
About Lightpoint Medical
Lightpoint Medical was founded in 2012 with the goal of becoming the world technology leader in targeted cancer surgery. The company's technology has the potential to detect cancer in real time during surgery, enabling surgeons to remove the cancerous tissue while sparing healthy tissue. The technology is based on administering the patient a cancer-targeted imaging drug and then detecting the cancer live during surgery.
Since the founding of the company, Lightpoint has achieved clinical trial data in multiple cancer types, regulatory clearance, and is well on its way to transforming the practice of cancer surgery.
For more information visit Lightpoint Medical
Follow us on Twitter
Follow us on LinkedIn